Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Tuček S[au]:

Search results

Items: 1 to 50 of 154

1.

Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening.

Vyskocil J, Tucek S, Kiss I, Fedorova L, Nevrlka J, Zdrazilova-Dubska L.

Int Immunopharmacol. 2019 Sep;74:105728. doi: 10.1016/j.intimp.2019.105728. Epub 2019 Jul 6.

PMID:
31288153
2.

Acetylsalicylic Acid and its Potential for Chemoprevention of Colorectal Carcinoma.

Podhorec J, Hrstka R, Bílek O, Tuček Š, Navrátil J, Michalová E, Vojtěšek B.

Klin Onkol. 2018 Winter;31(Suppl 2):77-81. doi: 10.14735/amko20182S77. Review.

PMID:
31023028
3.

[Kombinovaná léčba měkkotkáňového sarkomu v oblasti pánve].

Adámková Krákorová D, Tuček Š, Janíček P, Mahdal M, Šlampa P.

Rozhl Chir. Summer 2017;96(6):263-266. Czech.

PMID:
28931293
4.

Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management.

Krakorova DA, Kubackova K, Dusek L, Tomas T, Janicek P, Tucek S, Prausova J, Kiss I, Zambo I.

Pathol Oncol Res. 2018 Jul;24(3):623-630. doi: 10.1007/s12253-017-0291-6. Epub 2017 Aug 12.

PMID:
28803261
5.

[Anticoagulation and Thrombembolism During Bevacizumab Treatment--To Be Careful or Fearful?].

Tuček Š, Jurečková A, Tomášek J, Adámková Krákorová D, Halámková J, Pochop L.

Klin Onkol. 2015;28(4):293-5. Czech.

PMID:
26299745
6.

Prognostic value of scores based on malnutrition or systemic inflammatory response in patients with metastatic or recurrent gastric cancer.

Sachlova M, Majek O, Tucek S.

Nutr Cancer. 2014;66(8):1362-70. doi: 10.1080/01635581.2014.956261. Epub 2014 Oct 30.

PMID:
25356861
7.

[Malignant melanoma treated with radical chemotherapy, resemblance histology of melanoma to soft tissue sarcomas, case report].

Bílek O, Tuček S, Veselý K, Fabian P, Robešová B, Adámková Krákorová D, Lakomý R, Svoboda M, Jurečková A, Halámková J, Králová J, Sikulíncová L, Podhorec J, Tomášek J, Kiss I, Vyzula R.

Klin Onkol. 2013;26(1):42-6. Czech.

PMID:
23528172
8.

Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients.

Halamkova J, Kiss I, Pavlovsky Z, Tomasek J, Jarkovsky J, Cech Z, Bednarova D, Tucek S, Hanakova L, Moulis M, Zavrelova J, Man M, Benda P, Robek O, Kala Z, Penka M.

Neoplasma. 2013;60(2):151-9.

PMID:
23259783
9.

[Analysis of prognostic factors in osteosarcoma adult patients, a single institution experience].

Adamkova Krakorova D, Vesely K, Zambo I, Tucek S, Tomasek J, Jureckova A, Janicek P, Cerny J, Pazourek L, Ondrusek S, Selingerova I.

Klin Onkol. 2012;25(5):346-58. Czech.

PMID:
23102196
10.

[Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].

Halámková J, Kiss I, Tomášek J, Pavlovský Z, Tuček S, Penka M.

Vnitr Lek. 2012 Feb;58(2):129-34. Review. Czech.

PMID:
22463093
11.

Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients.

Halamkova J, Kiss I, Pavlovsky Z, Jarkovsky J, Tomasek J, Tucek S, Hanakova L, Moulis M, Cech Z, Zavrelova J, Penka M.

Hepatogastroenterology. 2011 Nov-Dec;58(112):1918-25. doi: 10.5754/hge10232.

PMID:
22234062
12.

Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients.

Halamkova J, Kiss I, Pavlovsky Z, Tomasek J, Jarkovsky J, Cech Z, Tucek S, Hanakova L, Moulis M, Zavrelova J, Man M, Benda P, Robek O, Kala Z, Penka M.

Neoplasma. 2011;58(5):377-85.

PMID:
21744990
13.

Multimodal oncological therapy comprising stents, brachytherapy, and regional chemotherapy for cholangiocarcinoma.

Andrašina T, Válek V, Pánek J, Kala Z, Kiss I, Tuček S, Slampa P.

Gut Liver. 2010 Sep;4 Suppl 1:S82-8. doi: 10.5009/gnl.2010.4.S1.S82. Epub 2010 Sep 10.

14.

Bile duct malignancies.

Tucek S, Tomasek J, Halámkova J, Kiss I, Andrasina T, Hemmelová B, Adámková-Krákorová D, Vyzula R.

Klin Onkol. 2010;23(4):231-41. Review.

PMID:
20806821
15.

Multiple promoters drive tissue-specific expression of the human M muscarinic acetylcholine receptor gene.

Krejci A, Bruce AW, Dolezal V, Tucek S, Buckley NJ.

J Neurochem. 2004 Oct;91(1):88-98.

16.

Role of receptor protein and membrane lipids in xanomeline wash-resistant binding to muscarinic M1 receptors.

Jakubík J, Tucek S, El-Fakahany EE.

J Pharmacol Exp Ther. 2004 Jan;308(1):105-10. Epub 2003 Oct 20.

PMID:
14569060
17.
19.
20.
21.

Modelling the consequences of receptor-G-protein promiscuity.

Tucek S, Michal P, Vlachová V.

Trends Pharmacol Sci. 2002 Apr;23(4):171-6. Review.

PMID:
11931992
22.

Chronic exposure of NG108-15 cells to amyloid beta peptide (A beta(1-42)) abolishes calcium influx via N-type calcium channels.

Kasparová J, Lisá V, Tucek S, Dolezal V.

Neurochem Res. 2001 Sep;26(8-9):1079-84.

PMID:
11699934
26.

Dual effects of muscarinic M2 receptors on the synthesis of cyclic AMP in CHO cells: background and model.

Tucek S, Michal P, Vlachova V.

Life Sci. 2001 Apr 27;68(22-23):2501-10.

PMID:
11392619
28.

Evidence for a tandem two-site model of ligand binding to muscarinic acetylcholine receptors.

Jakubik J, El-Fakahany EE, Tucek S.

J Biol Chem. 2000 Jun 23;275(25):18836-44.

30.

Subtype-selective inhibition of [methyl-3H]-N-methylscopolamine binding to muscarinic receptors by alpha-truxillic acid esters.

Lysíková M, Fuksová K, Elbert T, Jakubík J, Tucek S.

Br J Pharmacol. 1999 Jul;127(5):1240-6.

31.

Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors.

Michal P, Lysíková M, El-Fakahany EE, Tucek S.

Eur J Pharmacol. 1999 Jul 2;376(1-2):119-25.

PMID:
10440097
33.

Positive effects of allosteric modulators on the binding properties and the function of muscarinic acetylcholine receptors.

Tucek S, Jakubík J, Dolezal V, el-Fakahany EE.

J Physiol Paris. 1998 Jun-Aug;92(3-4):241-3. Review.

PMID:
9789816
34.

Heterologous regulation of muscarinic and beta-adrenergic receptors in rat cardiomyocytes in culture.

Myslivecek J, Lisá V, Trojan S, Tucek S.

Life Sci. 1998;63(13):1169-82.

PMID:
9763212
36.

Is the R and R dichotomy real?

Tucek S.

Trends Pharmacol Sci. 1997 Nov;18(11):414-6. No abstract available.

PMID:
9426467
37.

Effect of tacrine on intracellular calcium in cholinergic SN56 neuronal cells.

Dolezal V, Lisá V, Tucek S.

Brain Res. 1997 Sep 26;769(2):219-24.

PMID:
9374189
38.

Neurochemistry with microscopes: homage to Annica Dahlström.

Tucek S.

Neurochem Res. 1997 Aug;22(8):909-10. No abstract available.

PMID:
9239745
39.

Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.

Jakubík J, Bacáková L, El-Fakahany EE, Tucek S.

Mol Pharmacol. 1997 Jul;52(1):172-9.

PMID:
9224827
41.

Activation of muscarinic acetylcholine receptors via their allosteric binding sites.

Jakubík J, Bacáková L, Lisá V, el-Fakahany EE, Tucek S.

Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8705-9.

42.

Positive allosteric action of eburnamonine on cardiac muscarinic acetylcholine receptors.

Proska J, Tucek S.

Eur J Pharmacol. 1996 Jun 3;305(1-3):201-5.

PMID:
8813554
43.
45.

Positive and negative allosteric interactions on muscarinic receptors.

Hejnová L, Tucek S, el-Fakahany EE.

Eur J Pharmacol. 1995 Nov 30;291(3):427-30.

PMID:
8719429
46.

Positive allosteric action of alcuronium on solubilized cardiac muscarinic receptors.

Musílková J, Tucek S.

Neurochem Int. 1995 Oct-Nov;27(4-5):337-43.

PMID:
8845734
47.

Competition between positive and negative allosteric effectors on muscarinic receptors.

Proska J, Tucek S.

Mol Pharmacol. 1995 Oct;48(4):696-702.

PMID:
7476896
48.

Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors.

Jakubík J, Bacáková L, el-Fakahany EE, Tucek S.

J Pharmacol Exp Ther. 1995 Sep;274(3):1077-83.

PMID:
7562472
49.

Allosteric modulation of muscarinic acetylcholine receptors.

Tucek S, Proska J.

Trends Pharmacol Sci. 1995 Jun;16(6):205-12. Review.

PMID:
7652930

Supplemental Content

Support Center